Catalyst Calendar

Tue, Oct 6, 2026

1 updates

7:00 AM

Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation Final Phase 2 analysis explores potential of Libtayo before surgery (neoadjuvant treatment) for patients with

Presentation / Abstract • Phase 3ESMO poster presentations Sat, Oct 24, 2026, 12:00 PM CETregeneron.com

Thu, Oct 1, 2026

3 updates

REGN

11:35 AM

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy Results presented in a late-breaking plenary session at IGCS demonstrated a 73% objective response rate and 11-month median progression-free

Presentation / Abstract • Phase 1/2presentation Thu, Oct 1, 2026, 11:35 AM EDTregeneron.com

REGN

11:30 AM

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with

Trial Results • Phase 2presentation Thu, Oct 1, 2026regeneron.com

REGN

1:00 AM

Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron Regeneron to receive $1 billion upfront with potential for

regeneron.com

Thu, Sep 24, 2026

1 updates

REGN

4:05 PM

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open.

regeneron.com

Wed, Aug 19, 2026

2 updates

REGN

4:05 PM

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2026 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 9, 2026 Morgan Stanley 24 th Annual Global Healthcare Conference at

regeneron.com

REGN

1:58 PM

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from the OPTIMA trial demonstrating a 90% or greater reduction in new HO lesions at

regeneron.com

Fri, Jul 31, 2026

1 updates

REGN

7:00 AM

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

regeneron.com

Thu, Jul 30, 2026

1 updates

REGN

6:30 AM

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD ® U.S. net sales increased 52% to a new all-time high of $596 million Libtayo ® global net sales

regeneron.com